Nuformix said that it has received a Notice of Allowance for US Patent Application No. 17/051,592 titled, “Crystalline Tranilast Salts and Their Pharmaceutical Use.” The company has already been granted one patent covering crystalline forms of tranilast. According to Nuformix, pre-clinical studies of its NXP002 tranilast, which it is developing as a potential inhaled therapy for the treatment of ideopathic pulmonary fibrosis (IPF), are underway in order to “generate a more robust data package with the goal of increasing the value of the NXP002 asset to render it more attractive to licensing partners.”
Nuformix CEO Anne Brindley commented, “I am very pleased that we have received this Notice of Allowance from the US Patent Office meaning that this patent will proceed to be issued. This is an important endorsement of Nuformix’s discoveries and also strengthens the patent estate for our lead asset NXP002. The US is the largest market for IPF (over 60% of the global market) and thus this is a key step forward for the company and this asset.”
Read the Nuformix press release.
